Critical need for pharmacologic treatment options in NAFLD: A pediatric perspective

Abstract Nonalcoholic fatty liver disease (NAFLD) affects up to 70% of children with obesity and has become the number one etiology for liver transplant in the United States. Early, effective intervention is critical to prevent disease progression into adulthood. Yet, it is seldom achieved through l...

Full description

Saved in:
Bibliographic Details
Main Authors: Chance S. Friesen (Author), Sherwin S. Chan (Author), Jonathan B. Wagner (Author), Chelsea Hosey‐Cojocari (Author), Iván L. Csanaky (Author), Valentina Shakhnovich (Author)
Format: Book
Published: Wiley, 2021-05-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Nonalcoholic fatty liver disease (NAFLD) affects up to 70% of children with obesity and has become the number one etiology for liver transplant in the United States. Early, effective intervention is critical to prevent disease progression into adulthood. Yet, it is seldom achieved through lifestyle modification alone. Thus, children must be included in NAFLD pharmacology trials, which, to date, continue to focus primarily on adult populations. This commentary serves as a call to action.
Item Description:1752-8062
1752-8054
10.1111/cts.12952